Review Article
Salvage Therapy of Multiple Myeloma: The New Generation Drugs
Table 2
The most active proteasome inhibitors currently tested in relapsed/refractory myeloma patients.
| | Drug | Bond to proteasome | Route of administration |
| | Carfilzomib | Reversible | i.v. | | Marizomib (NPI-0052) | Irreversible | i.v.; oral | | Ixazomib (MLN9708/MLN2238) | Reversible | i.v.; oral | | Oprozomib (ONX0912) | Irreversible | oral | | Delanzomib (CEP-18770) | Reversible | i.v.; oral |
|
|
